These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31084320)

  • 1. Getting the Gist Across Is Enough for Informed Consent for Acute Stroke Thrombolytics.
    Skolarus LE; O'Brien A; Meurer WJ; Zikmund Fisher BJ
    Stroke; 2019 Jun; 50(6):1595-1597. PubMed ID: 31084320
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
    Liang BA; Lew R; Zivin JA
    Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Litigation regarding tPA and stroke.
    Pilcher CA
    Ann Emerg Med; 2009 Mar; 53(3):404; author reply 404-5. PubMed ID: 19231673
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis.
    Xu H; De Silva DA; Woon FP; Ong MEH; Matchar DB; Bettger JP; Laskowitz DT; Xian Y
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105551. PubMed ID: 33348248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informed Consent for Intravenous Tissue Plasminogen Activator in New York State Designated Stroke Centers.
    Weintraub MI; Colello AD; Johnson SA; McClellan F; Cole SP; Benesch C; Rudolph SH; Levine SR
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1274-1279. PubMed ID: 28189569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical Justification for Deferral of Consent in the AcT Trial for Acute Ischemic Stroke.
    Faris H; Dewar B; Dowlatshahi D; Ramji A; Kenney C; Page S; Buck B; Hill MD; Coutts SB; Almekhlafi M; Sajobi T; Singh N; Sehgal A; Swartz RH; Menon BK; Shamy M
    Stroke; 2022 Jul; 53(7):2420-2423. PubMed ID: 35603597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consent to thrombolysis in acute ischaemic stroke: from trial to practice.
    Ciccone A
    Lancet Neurol; 2003 Jun; 2(6):375-8. PubMed ID: 12849154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonstroke treatment.
    Landau WM
    Arch Neurol; 2006 Oct; 63(10):1506; author reply 1506-7. PubMed ID: 17030674
    [No Abstract]   [Full Text] [Related]  

  • 9. Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice.
    Rosenbaum JR; Bravata DM; Concato J; Brass LM; Kim N; Fried TR
    Stroke; 2004 Sep; 35(9):e353-5. PubMed ID: 15243145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist.
    Berekashvili K; Zha AM; Abdel-Al M; Zhang X; Soomro JH; Prater SJ; Grotta JC
    Stroke; 2020 Feb; 51(2):663-665. PubMed ID: 31771461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytics for hyperacute stroke in children.
    Amlie-Lefond C; Fullerton HJ
    Pediatr Hematol Oncol; 2009; 26(3):103-7. PubMed ID: 19382031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.
    Samaniego EA; Linfante I; Dabus G
    Tech Vasc Interv Radiol; 2012 Mar; 15(1):41-6. PubMed ID: 22464301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consent for intravenous thrombolysis in acute stroke: review and future directions.
    White-Bateman SR; Schumacher HC; Sacco RL; Appelbaum PS
    Arch Neurol; 2007 Jun; 64(6):785-92. PubMed ID: 17562926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice variation in the informed consent procedure for thrombolysis in acute ischemic stroke: a survey among neurologists and neurology residents.
    Zonjee VJ; Slenders JPL; de Beer F; Visser MC; Ter Meulen BC; Van den Berg-Vos RM; van Schaik SM
    BMC Med Ethics; 2021 Aug; 22(1):114. PubMed ID: 34433444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined stroke trial data confirms that early treatment with thrombolytics improves outcomes.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Apr; 15(7):8-9. PubMed ID: 15101394
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical inquiries. When should patients with stroke receive thrombolytics?
    Adair G; Grant J; Pandhi N; Saunders R; Sadowsky I; West B; Kerns JW; Knight K; Richmond J
    J Fam Pract; 2004 Aug; 53(8):656, 658-9. PubMed ID: 15298842
    [No Abstract]   [Full Text] [Related]  

  • 17. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
    Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR
    BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute stroke management.
    Ducharme J; Currie T; Ovens H; Rutledge T; Thompson J
    Can Fam Physician; 2001 Dec; 47():2458. PubMed ID: 11785275
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
    Cremer S; Berliner Y; Warren D; Jones AE
    CJEM; 2008 Nov; 10(6):575-8. PubMed ID: 19000355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
    Brown DL; Barsan WG; Lisabeth LD; Gallery ME; Morgenstern LB
    Ann Emerg Med; 2005 Jul; 46(1):56-60. PubMed ID: 15988427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.